Telara Pharma
Bringing cilastatin to clinical trials for the treatment of inflammatory disorders
Bringing cilastatin to clinical trials for the treatment of inflammatory disorders
Telara Pharma is a pharmaceutical startup founded in 2020 with a mission to revolutionize kidney disease treatment. Inspired by the pioneering work of the late Dr. Alberto Tejedor Jorge, the company focuses on developing innovative therapeutic approaches for acute kidney injury caused by toxins, sepsis, and acute kidney failure related to sepsis. The recent €100.00K Seed Round investment from GENESIS Biomed on 11 May 2021 underscores the industry's confidence in Telara Pharma's potential. The startup's commitment to addressing unmet medical needs and continuing Dr. Jorge's legacy positions it as a promising player in the pharmaceutical industry. With its strong focus on innovation and nephroprotection, Telara Pharma is poised to make a significant impact in the field of kidney disease treatment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €100.00K | 1 |
|
11 May 2021 |
No recent news or press coverage available for Telara Pharma.
-(ACHFF:OTCQB)-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
